{"id":"W2108147025","doi":"10.1056/nejmoa051287","title":"Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis B","year":2006,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Hepatitis B Virus Studies","field":"Medicine","cited_by":1191,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Sanofi Pasteur; New England Research Institutes; National Institutes of Health; American Association for the Study of Liver Diseases; Gilead Sciences; Valeant Pharmaceuticals International; Sanofi; GlaxoSmithKline; Bristol-Myers Squibb","keywords":"Entecavir; Lamivudine; Medicine; HBeAg; Gastroenterology; Adefovir; Internal medicine; Hepatitis B; Telbivudine; Hepatitis B virus; Virology; Virus; HBsAg","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null}